| Date |
Title |
Rating |
| 2009-12-31 |
FDA evaluates Phase III randomized trial in acute myeloid leukemia |
None |
| 2009-12-30 |
Santarus submits rifamycin SV MMX IND to the FDA |
None |
| 2009-12-30 |
Phase 3 trial of figitumumab discontinued by Pfizer |
None |
| 2009-12-29 |
Advaxis reports 3-year survival data from its ADXS11-001 Phase I trial for cervical cancer |
None |
| 2009-12-29 |
Promising results from Soligenix' RiVax vaccine against ricin toxin |
None |
| 2009-12-28 |
SVA submits the first clinical trial application for HFMD vaccine in China |
None |
| 2009-12-24 |
SemBioSys Genetics' Apo AI(Milano) program progress update |
None |
| 2009-12-24 |
Forest Laboratories acquires additional rights to NXL 104 beta-lactamase inhibitor |
None |
| 2009-12-24 |
Merck discontinues MK-1903 niacin receptor agonist development program with Arena Pharmaceuticals |
5 |
| 2009-12-23 |
Synta Pharmaceuticals initiates STA-9090 Phase 2 clinical trial for GIST |
None |
| 2009-12-23 |
Positive results from Alimera Sciences' Iluvien FAME trial for DME |
4.5 |
| 2009-12-23 |
Rigel Pharmaceuticals announces milestone payment from Daiichi Sankyo |
None |
| 2009-12-23 |
Compugen, Pfizer enter into multi-target collaboration |
None |
| 2009-12-23 |
ARCA biopharma submits Gencaro trial protocol for review under the FDA’s SPA process |
None |
| 2009-12-23 |
US Phase 2 clinical trial of RVX-208 commenced by Resverlogix |
None |
| 2009-12-22 |
Eritoran well tolerated in Phase II trial for severe sepsis |
None |
| 2009-12-22 |
Effectiveness of Genfit’s GFT505 clinical drug candidate questioned |
None |
| 2009-12-22 |
Study results of CSL’s pandemic H1N1 2009 vaccine published in JAMA |
None |
| 2009-12-22 |
DSM BioSolutions to manufacture Mayoly Spindler's 'MS1819' lipase biotherapeutic |
None |
| 2009-12-22 |
LEO Pharma announces positive results for two Phase III AK clinical trials |
None |
| 2009-12-21 |
Results from Phase I trial of Bryan Oncor's targeted radiopharmaceutical therapy reported |
None |
| 2009-12-21 |
Oxford Finance to provide Titan Pharmaceuticals a $3M term loan |
None |
| 2009-12-21 |
Neurocrine to advance its NBI-98854 VMAT2 Inhibitor into a multiple repeated dose Phase 1 study |
None |
| 2009-12-21 |
Positive interim results from Idera Pharmaceuticals' IMO-2125 Phase 1 clinical trial for HCV |
5 |
| 2009-12-21 |
Teva Pharmaceutical Industries, OncoGenex Pharmaceuticals announce collaboration in cancer therapy |
None |
| 2009-12-21 |
OncoGenex Pharmaceuticals to pay Isis Pharmaceuticals $10M for license of OGX-011 to Teva Pharmaceutical Industries |
3 |
| 2009-12-21 |
CPEX Pharmaceuticals completes enrollment in Nasulin Phase 2a clinical trial |
None |
| 2009-12-21 |
Eli Lilly, Incyte announce collaboration for development and commercialization of INCB28050 oral inhibitor |
None |
| 2009-12-21 |
Intra-Cellular Therapies announces results of its ITI-007 antipsychotic drug Phase I study |
2.3 |
| 2009-12-21 |
Positive interim results from Medicago's H5N1 vaccine Phase I human clinical trial |
None |
| 2009-12-21 |
Soligenix commences SGX201 Phase 1/2 clinical trial for acute radiation enteritis prevention |
None |
| 2009-12-21 |
Preliminary results from Phase III study of afamelanotide in EPP announced |
None |
| 2009-12-18 |
Taro Pharmaceutical Industries initiates its T2007 non-sedating barbiturate compound Phase I clinical trials |
None |
| 2009-12-18 |
U.S. health officials announce shift in focus of prep trial in Botswana |
None |
| 2009-12-18 |
PolyMedix completes first two segments of its PMX-30063 antibiotic drug candidate Phase 1B study |
None |
| 2009-12-18 |
Flamel Technologies initiates IFN-alpha-2b XL Phase 2a clinical trial for HCV |
None |
| 2009-12-18 |
Initial data from REVLIMID Phase III trial in multiple myeloma patients announced |
None |
| 2009-12-18 |
Phase 2 clinical study of STA-9090 in NSCLC initiated |
None |
| 2009-12-18 |
ARIAD Pharmaceuticals completes enrollment of patients for Phase 3 clinical trial of ridaforolimus |
None |
| 2009-12-17 |
Arno Therapeutics announces dosing of first patient in Phase II clinical study of AR-67 |
None |
| 2009-12-17 |
Update on Phase 2 clinical trial of oral interferon announced by Amarillo Biosciences |
None |
| 2009-12-17 |
AlphaRx, Venturepharm sign supply agreement for ARX1088's API |
None |
| 2009-12-17 |
Positive results from DURECT's Phase IIb POSIDUR clinical trial for post-surgical pain |
None |
| 2009-12-17 |
Alcon increases its financial support for NovaBay Pharmaceuticals' research and development efforts |
None |
| 2009-12-17 |
Anadys Pharmaceuticals reports positive 4-week results from its ANA598 Phase II study for HCV |
None |
| 2009-12-17 |
BDSI's BEMA Buprenorphine Phase 2 study meets primary efficacy endpoint |
None |
| 2009-12-17 |
Sanofi Pasteur uses PHT’s LogPad System and StudyWorks online portal for its Phase II trial |
None |
| 2009-12-17 |
Roche discloses results of two of eight taspoglutide T-emerge phase III studies in diabetes patients |
2 |
| 2009-12-17 |
Top-line efficacy and safety results from Phase 2b clinical trial of XIAFLEX announced |
None |
| 2009-12-16 |
Phase 3 registration clinical trial for perifosine initiated by Keryx Biopharmaceuticals |
None |
| 2009-12-16 |
NanoBio, GSK partner to develop and commercialize novel cold sore treatment compound |
1 |
| 2009-12-16 |
Nanotherapeutics acquires Ramoplanin clinical program from Oscient Pharmaceuticals |
None |
| 2009-12-16 |
ChemoCentryx commences enrollment in CCX354 Phase 2 clinical trial for RA |
None |
| 2009-12-16 |
Advanced Life Sciences Holdings' Restanza promising against tularemia |
None |
| 2009-12-16 |
Keryx Biopharmaceuticals initiates Phase 3 registration clinical trial for perifosine |
None |
| 2009-12-16 |
Positive results from Onset Therapeutics' BenzEFoam Emollient Foam skin moisturization study |
None |
| 2009-12-16 |
Xencor's initiation of novel monoclonal antibody human clinical trial triggers milestone payment from Pfizer |
None |
| 2009-12-16 |
Naurex' GLYX-13 demonstrates antidepressant-like and anxiolytic-like activity without CNS-related side effects |
None |
| 2009-12-16 |
Naurex commences dosing in its GLYX-13 Phase I clinical trial for treatment-resistant depression |
None |
| 2009-12-16 |
Positive results from Auxilium Pharmaceuticals' XIAFLEX Peyronie's disease phase IIb trial |
None |
| 2009-12-16 |
Patients involved in Novelos Therapeutics' pivotal Phase III trial live longer than expected |
5 |
| 2009-12-16 |
Cancer Research UK's phase I trial results of CHT25 published in Clinical Cancer Research |
None |
| 2009-12-16 |
ThromboGenics completes enrollment in second microplasmin Phase III trial |
None |
| 2009-12-15 |
DSMB approves advancement of PLX-PAD to intermediate dose level in Phase I clinical trial for CLI treatment |
None |
| 2009-12-15 |
BioAlliance Pharma SA to enter Phase II clinical trial for clonidine Lauriad and Phase I clinical trial for AMEP |
None |
| 2009-12-15 |
Advaxis to collaborate with GOG in Phase II clinical trial of ADXS11-001 |
None |
| 2009-12-15 |
Positive results from study comparing exenatide once weekly to BYETTA |
3 |
| 2009-12-15 |
Femta Pharmaceuticals, Lonza Group collaborate in cGMP production of FM101 antibody |
None |
| 2009-12-15 |
Can-Fite BioPharma to commence Glaucoma Phase II clinical study in Israel |
4 |
| 2009-12-15 |
University of Wisconsin IRB approves GenSpera's G-202 Phase I study for cancer |
None |
| 2009-12-15 |
Encouraging results from DAVANAT in combination with chemotherapies and biologics |
None |
| 2009-12-15 |
Celgene announces positive data from its apremilast Phase IIb study for plaque-type psoriasis |
None |
| 2009-12-15 |
Lytix Biopharma AS receives approval to commence Phase I clinical trials of Oncopore |
None |
| 2009-12-15 |
QLT commences enrollment in QLT091001 Phase Ib trial of LCA pediatric patients |
None |
| 2009-12-15 |
Seattle Genetics announces collaboration to globally develop and commercialize brentuximab vedotin |
None |
| 2009-12-15 |
Molecular Partners closes its CHF 46 million Series B equity investment round |
None |
| 2009-12-15 |
Update on new clinical developments and other initiatives related to Ceplene |
None |
| 2009-12-15 |
Modifications to Phase II study AD201 and open label extension study AD251 for ELND005 notified |
None |
| 2009-12-15 |
Phase III clinical trial evaluating darusentan misses its co-primary efficacy endpoints |
None |
| 2009-12-15 |
Updated clinical data from Phase 2 study evaluating oral ridaforolimus presented |
None |
| 2009-12-14 |
Oncolytics Biotech develops REOLYSIN for patients affected by hard-to-treat cancers |
3.5 |
| 2009-12-14 |
Genentech announces Phase III study of Avastin in women treated with chemotherapy for advanced breast cancer |
5 |
| 2009-12-14 |
AVAC: MDP 301 effectiveness trial finds no evidence that PRO 2000 microbicide reduces HIV infection |
None |
| 2009-12-14 |
Pfizer announces results from studies evaluating neratinib |
None |
| 2009-12-14 |
Results from Phase 2 trial evaluating Nexavar with capecitabine and paclitaxel presented |
None |
| 2009-12-14 |
Tulane Cancer Center starts randomizing patients in phase III clinical study of Alpharadin |
5 |
| 2009-12-14 |
Combination therapy improves overall survival in women with advanced breast cancer |
None |
| 2009-12-14 |
Ipsen announces preliminary results of phase I trial in metastatic breast cancer with BN83495 |
None |
| 2009-12-14 |
Genentech announces positive results from Phase II study of T-DM1 |
None |
| 2009-12-14 |
Incyte announces positive results from ongoing Phase I/II clinical trial for INCB7839 |
None |
| 2009-12-14 |
ImmunoGen announces the presentation of positive trastuzumab-DM1 clinical data |
None |
| 2009-12-13 |
Positive Phase 2 study results of CDX-011 reported by Celldex Therapeutics |
None |
| 2009-12-13 |
Positive interim results of ARRY-380 in Phase 1 trial announced |
None |
| 2009-12-13 |
Clinical trial of 2009 H1N1 influenza vaccine |
None |
| 2009-12-12 |
Enrollment of patients for Phase IIb clinical trial of WBI-1001 commenced |
None |
| 2009-12-12 |
Phase 1 clinical trial of iCo-007 demonstrates positive safety profile |
None |
| 2009-12-11 |
Phase 2 pivotal trial of AC220 initiated by Ambit Biosciences |
None |
| 2009-12-11 |
Zevalin clinical data presented at 2009 ASH meeting |
None |
| 2009-12-11 |
Genentech terminates dacetuzumab collaboration agreement with Seattle Genetics |
1 |
| 2009-12-11 |
Pfizer announces IES analysis of Aromasin in breast cancer recurrence |
None |
| 2009-12-11 |
ThromboGenics initiates Phase II trial of microplasmin for wet AMD |
None |
| 2009-12-11 |
Genentech and Biogen Idec report positive outcome from ocrelizumab-MTX combination study in RA |
None |
| 2009-12-11 |
Tasigna demonstrates greater efficacy over Gleevec in chronic Ph+ CML patients |
None |
| 2009-12-11 |
Initiation of multi-national Phase III study of Stimuvax announced |
1 |
| 2009-12-11 |
DMC recommends Novartis and Nordic Bioscience to continue oral calcitonin Phase III studies |
None |
| 2009-12-11 |
Fulvestrant 500 mg reduces risk of disease progression in women with metastatic breast cancer |
None |
| 2009-12-10 |
Positive results from BioAlliance Pharma's acyclovir Lauriad phase III trial |
None |
| 2009-12-10 |
FDA approves Azaya Therapeutics' Taxotere for Phase I clinical study |
None |
| 2009-12-10 |
DMC recommends Emisphere Technologies' to proceed with oral calcitonin trial for OP and OA |
None |
| 2009-12-10 |
Targacept commences TC-5619 Phase 2 study of cognitive dysfunction in schizophrenia |
None |
| 2009-12-10 |
Merck commences Stimuvax Phase 3 trial in Asian patients with NSCLC |
1 |
| 2009-12-10 |
Schizophrenia: Once-monthly INVEGA SUSTENNA not inferior to bi-weekly RISPERDAL CONSTA |
5 |
| 2009-12-10 |
Second-quarter fiscal 2010 results announced by Peregrine Pharmaceuticals |
None |
| 2009-12-10 |
Fourth-quarter and full year fiscal 2009 results announced by Biodel |
None |
| 2009-12-10 |
Immune-based treatment promising for AD |
None |
| 2009-12-10 |
Rituxan improves patients with previously untreated CLL, shows Phase III study CLL8 |
None |
| 2009-12-10 |
Results from Tulip PETAL Study of elagolix announced by Neurocrine Biosciences |
None |
| 2009-12-10 |
Initiation of dose-finding study to evaluate safety and efficacy of MP4OX treatment |
None |
| 2009-12-10 |
Second pivotal Phase 3 trial to evaluate investigational Lp-PLA2 inhibitor darapladib initiated |
None |
| 2009-12-09 |
Additional data from ALS patients enrolled in confirmatory Phase III STAR trial announced |
None |
| 2009-12-09 |
Roche to present data on its Herceptin, Avastin and T-DM1 studies at CTRC-AACR Symposium |
None |
| 2009-12-09 |
RegeneRx Biopharmaceuticals completes Phase I trial evaluating systemic administration of RGN-352 |
None |
| 2009-12-09 |
Watson Pharmaceuticals' RAPAFLO demonstrates safety and tolerability in BPH treatment |
None |
| 2009-12-09 |
Osteologix to file an European Marketing Application for its NB S101 strontium therapy |
None |
| 2009-12-09 |
Preliminary data from Phase 2 clinical trial of ZFP Therapeutic program presented |
None |
| 2009-12-09 |
Clinical results from Phase 2 study of KNS-760704 presented by Knopp Neurosciences |
5 |
| 2009-12-09 |
Clinical trial results demonstrate greater efficacy of nilotinib over imatinib for Ph+ CML |
None |
| 2009-12-09 |
VERTICAL Phase II trial results for NHL released |
5 |
| 2009-12-09 |
Recruitment complete in Oxagen's OC000459 IIb clinical trial for asthma |
None |
| 2009-12-09 |
Memgen announces positive clinical data of ISF35 with chemotherapy |
None |
| 2009-12-09 |
TGen and Scottsdale Healthcare test PHA-848125ac drug for thymic cancer |
None |
| 2009-12-09 |
University of Texas launches phase II clinical trial to test stem-cell-based therapy on injured heart muscle |
None |
| 2009-12-09 |
Data evaluating combination therapy with REVLIMID and rituximab in patients with NHL presented |
None |
| 2009-12-09 |
Mozobil with chemotherapy may have a therapeutic impact on leukemic cells, reveals study |
None |
| 2009-12-09 |
Multiple clinical study results of ABRAXANE to be presented by Abraxis BioScience |
None |
| 2009-12-09 |
Phase II clinical trial results of Doxorubicin Transdrug announced |
None |
| 2009-12-09 |
GSK updates long-term survival data of BEXXAR Therapeutic Regimen for Non-Hodgkin's lymphoma |
None |
| 2009-12-09 |
Neoprobe completes Phase 3 Lymphoseek clinical trial on breast cancer patients |
None |
| 2009-12-08 |
Updated clinical data of Calistoga Pharmaceuticals’ delta selective PI3K inhibitor presented |
None |
| 2009-12-08 |
Micromet presents final data from its blinatumomab Phase 2 study for ALL |
None |
| 2009-12-08 |
The National Fragile X Foundation awards $100,000 grant for study of minocycline in FXS children |
None |
| 2009-12-08 |
Updated data from Allos Therapeutics' ongoing FOLOTYN study |
None |
| 2009-12-08 |
Hemaquest Pharmaceuticals' HQK-1001 holds promise for sickle cell disease and beta thalassemia |
3 |
| 2009-12-08 |
Hemodynamic Therapeutics' HTI-101 clinical study for treatment-resistant hypertension meets primary endpoint |
None |
| 2009-12-08 |
Interim data from Geron's GRNVAC1 phase II trial for AML presented |
None |
| 2009-12-08 |
Encouraging results from Semafore Pharmaceuticals' SF1126 Phase I dose-escalation trial for myeloma |
None |
| 2009-12-08 |
Clinical trial results of VELCADE based combinations for MM to be presented at the ASH meeting |
None |
| 2009-12-08 |
Phase 2 study of carfilzomib shows promising results in patients with refractory multiple myeloma |
None |
| 2009-12-08 |
Study data of REVLIMID-dexamethasone combination therapy for high-risk smoldering multiple myeloma |
None |
| 2009-12-08 |
Enrollment of patients for Phase I/IIa clinical study of Interleukin-7 commenced |
5 |
| 2009-12-08 |
Positive data from Onconova Therapeutics' ON 01910.Na trial for advanced MDS |
5 |
| 2009-12-08 |
Positive data from ARIAD Pharmaceuticals' ongoing AP24534 study in advanced hematological cancer patients |
None |
| 2009-12-08 |
SOLESTA pivotal study meets primary endpoints for fecal incontinence treatment |
None |
| 2009-12-08 |
Phase III CLL8 trial shows Rituxan plus FC chemotherapy improves patients with CLL |
None |
| 2009-12-08 |
Ambit Biosciences presents study results of its AC220 FLT3 inhibitor for AML |
None |
| 2009-12-08 |
Neovacs announces initiation of a Phase IIa clinical study of TNFα Kinoid immunotherapy |
None |
| 2009-12-08 |
Two abstracts describing preclinical studies with GMI-1070 selected for oral presentations |
None |
| 2009-12-08 |
ImmunoGen's SAR3419 holds hope for B-cell non-Hodgkin’s lymphoma |
None |
| 2009-12-08 |
Gentium presents evaluation results of Defibrotide for VOD at the ASH conference |
None |
| 2009-12-08 |
Study results comparing REVLIMID regimen to stem cell transplant in multiple myeloma patients |
None |
| 2009-12-08 |
Galapagos NV receives milestone payment to initiate Phase I clinical trial of GLPG0555 drug |
None |
| 2009-12-08 |
Additional data from ChemoCentryx' study of Traficet-EN in Crohn's disease patients |
None |
| 2009-12-08 |
Potentially promising data from Phase I/II study of elotuzumab presented at ASH 2009 |
None |
| 2009-12-08 |
PolyMedix to present data on its heptagonist compounds |
None |
| 2009-12-08 |
Amgen announces results from first Phase 1/2 study of Nplate |
None |
| 2009-12-08 |
CAM314 randomized Phase 3 clinical trial results released |
5 |
| 2009-12-08 |
Data from two phase Ib clinical trials of dacetuzumab for DLBCL reported |
None |
| 2009-12-08 |
Phase II clinical trial results reveal positive effects of omacetaxine against CML |
None |
| 2009-12-08 |
Results of preclinical studies evaluating AC220 to be presented at ASH annual meeting |
None |
| 2009-12-08 |
Carfilzomib shows noteworthy responses and low side effects among multiple myeloma patients |
None |
| 2009-12-08 |
Biogen Idec's BG-12 achieves key milestones in clinical trials for MS and RA |
None |
| 2009-12-08 |
Phase 1 study results of TRU-016 in patients with CLL announced |
None |
| 2009-12-07 |
Results from CytRx's Phase 2 STAR-1 registration clinical trial for tamibarotene announced |
None |
| 2009-12-07 |
Phase 3 results for European efficacy trial Z-036 in BPH with cetrorelix pamoate reported |
None |
| 2009-12-07 |
New data from Allos Therapeutics' FOLOTYN trial for PTCL |
None |
| 2009-12-07 |
Study data of Perifosine + Bortezomib combination in multiple myeloma patients presented |
None |
| 2009-12-07 |
Incyte's INCB18424 provides previously unachievable clinical benefits in myelofibrosis patients |
5 |
| 2009-12-07 |
Interim data from Celator Pharmaceuticals' CPX-351 trial presented at the ASH meeting |
None |
| 2009-12-07 |
Synta Pharmaceuticals announces study results of elesclomol |
None |
| 2009-12-07 |
Æterna Zentaris reports Phase 3 results of its cetrorelix pamoate Z-036 trial for BPH |
None |
| 2009-12-07 |
Encouraging data from Seattle Genetics' phase I trial of brentuximab vedotin |
None |
| 2009-12-07 |
Micromet to present new data from its blinatumomab Phase 1 trial at the ASH meeting |
None |
| 2009-12-07 |
UCB presents data on Vimpat AED at AES meeting |
None |
| 2009-12-07 |
Preclinical and Phase I data for TG-0054 presented by TaiGen Biotechnology |
None |
| 2009-12-07 |
Dabigatran etexilate prevents recurrent VTE with less bleeding than warfarin |
None |
| 2009-12-07 |
Positive data from Gloucester Pharmaceuticals' ISTODAX study presented at the ASH meeting |
None |
| 2009-12-07 |
J&JPRD announces clinical results of new oral anticoagulant therapy for venous thromboembolism |
None |
| 2009-12-07 |
Positive clinical data from Phase II study of elacytarabine in patients with AML reported |
None |
| 2009-12-07 |
Updated results from phase III EXTEND clinical trial of pixantrone released |
None |
| 2009-12-07 |
Phase I/II clinical trial of Multimeric-001 Universal Flu Vaccine successful |
None |
| 2009-12-07 |
ChemGenex Pharmaceuticals presents clinical results of Omapro drug at ASH meeting |
None |
| 2009-12-07 |
Presentation of preclinical data demonstrating the combination of ISTODAX and Velcade announced |
None |
| 2009-12-07 |
Poster summarizing clinical trial data regarding SB-743921 presented by Cytokinetics |
None |
| 2009-12-07 |
Researchers explore optimal induction therapies for managing blood cancer |
None |
| 2009-12-07 |
VELCADE based regimens are cost-effective for payers and patients, finds study |
None |
| 2009-12-07 |
New analyses of data from Allos Therapeutics’ pivotal PROPEL trial of FOLOTYN reported |
None |
| 2009-12-07 |
Alexion Pharmaceuticals announces positive data from AEGIS study of Soliris |
None |
| 2009-12-07 |
Amgen announces results from three studies on the safety and efficacy of Nplate |
None |
| 2009-12-07 |
Updated safety data from Phase 2b 003-A1 study of carfilzomib announced |
None |
| 2009-12-06 |
ImmunoGen reports encouraging clinical data of IMGN901 |
None |
| 2009-12-06 |
Positive final data from Phase 2 study of ISTODAX presented |
None |
| 2009-12-06 |
Dabigatran etexilate offers effective therapy to prevent recurrent VTE |
None |
| 2009-12-06 |
Bortezomib can improve control of GVHD and immune system recovery |
None |
| 2009-12-05 |
Investigators to discuss data presentations on carfilzomib inhibitor at ASH Annual Meeting |
None |
| 2009-12-05 |
Oxygen Biotherapeutics commences enrollment in clinical trial of Oxycyte emulsion for TBI |
None |
| 2009-12-04 |
Pre-clinical study data of Stemline Therapeutics' IL-3R targeting agents to be presented at the ASH meeting |
None |
| 2009-12-04 |
Results from Phase III pivotal study of FIRMAGON presented |
None |
| 2009-12-04 |
Pfizer to present study findings from its expanded breast cancer portfolio |
None |
| 2009-12-04 |
Preclinical data of Curis' HSP 90 inhibitor published |
None |
| 2009-12-04 |
Allos Therapeutics, Idis collaborate in named patient program for FOLOTYN |
None |
| 2009-12-04 |
Type 2 diabetics with CAD experience greater antiplatelet activity with prasugrel compared to clopidogrel |
None |
| 2009-12-04 |
Genzyme announces reopening of enrollment in its Pompe disease ATAP program |
None |
| 2009-12-03 |
Lightlake Therapeutics granted ethical approval for gene testing subjects in obesity treatment trial |
None |
| 2009-12-03 |
Last patient visit complete in VIA Pharmaceuticals' Phase 2 FDG-PET trial |
None |
| 2009-12-03 |
iCo Therapeutics to present an overview of its iCo-007 VEGF "+" agent at the ISOPT conference |
None |
| 2009-12-03 |
Initial positive data from Amira Pharmaceuticals' Phase 1 clinical study of AM461 DP2 antagonist |
None |
| 2009-12-03 |
Hyperion Therapeutics commences enrollment in its HPN-100 episodic hepatic encephalopathy trial |
None |
| 2009-12-03 |
Update on Celsion's ThermoDox Phase III “HEAT” trial for HCC |
None |
| 2009-12-03 |
Tripep receives approval to extend ChronVac-C study |
None |
| 2009-12-03 |
More than 80 abstracts highlighting Bristol-Myers Squibb's oncology compound to be presented |
None |
| 2009-12-03 |
European Phase III clinical trial of budesonide MMX completes patient enrollment |
None |
| 2009-12-02 |
Favorable initial results from Novavax' 2009 H1N1 VLP pandemic influenza vaccine Phase II study |
None |
| 2009-12-02 |
FDA grants Fast Track designation for AEterna Zentaris' perifosine |
None |
| 2009-12-02 |
Genta to supply Ganite for new CF clinical trial |
None |
| 2009-12-02 |
Sepracor to present clinical study data of STEDESA at the 2009 AES meeting |
None |
| 2009-12-02 |
New data demonstrating the strength of Novartis' hematology portfolio to be presented |
None |
| 2009-12-02 |
University of Texas M.D. Anderson Cancer Center and Stemline Therapeutics enter into research collaboration |
None |
| 2009-12-02 |
Updated results from MYTHOS clinical trial of RenalGuard presented at AHA meeting |
None |
| 2009-12-02 |
Roche announces results of phase III taspoglutide study in diabetes patients |
2 |
| 2009-12-02 |
Results from second Phase III placebo controlled study of EXPAREL announced |
4 |
| 2009-12-02 |
Data from brentuximab vedotin and dacetuzumab programs to be presented by Seattle Genetics |
None |
| 2009-12-02 |
New data on pixantrone Phase III trial in non-Hodgkin's lymphoma to be presented |
None |
| 2009-12-02 |
Results from ongoing clinical trial of ISF35 to be presented at ASH annual meeting |
None |
| 2009-12-02 |
Ohr Pharmaceutical to present interim data from ongoing Phase II clinical trial of OHR/AVR118 |
None |
| 2009-12-01 |
CRO to run CEL-SCI's upcoming Phase III clinical trial |
None |
| 2009-12-01 |
Calistoga Pharmaceuticals to present data on its CAL-101 inhibitor at the 51st ASH meeting |
None |
| 2009-12-01 |
Palatin Technologies issued U.S. patent covering its lead heart failure drug candidate |
None |
| 2009-12-01 |
Positive results from Ardea Biosciences' ongoing drug-drug interaction study of RDEA594 and febuxostat |
None |
| 2009-12-01 |
Bioequivalence and comparable toxicity of ADVENTRX Pharmaceuticals' ANX-514 and Taxotere affirmed |
5 |
| 2009-12-01 |
Positive data from Provectus Pharmaceuticals' psoriasis and atopic dermatitis trials |
None |
| 2009-12-01 |
StemCyte concludes exclusive license and commercialization agreement with Academia Sinica |
None |
| 2009-12-01 |
Amgen to present updated data on Nplate at the 2009 ASH meeting |
5 |
| 2009-12-01 |
Completion of Phase I study of CPSI-2364 announced by Cytokine PharmaSciences |
None |
| 2009-12-01 |
University of Navarra Hospital launches clinical trials to assess the efficacy of immunotherapy treatment |
None |
| 2009-12-01 |
ChemGenex Pharmaceuticals to present updated clinical data from its clinical trials with Omapro |
None |